Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hiltonol + SL701
- Development stage
- Unknown
- Lead developer
- Stemline Therapeutics
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Hiltonol + SL701 (also known as Poly-ICLC + SL701) is a combination immunotherapy co-developed by Stemline Therapeutics and Oncovir for the treatment of glioblastoma (GBM) and other gliomas. The combination consists of SL701, an off-the-shelf, synthetic multi-peptide cancer vaccine targeting three glioma-associated antigens overexpressed in glioblastoma—interleukin-13 receptor alpha-2 (IL-13Rá2), EphA2, and survivin—and Hiltonol (poly-ICLC), a synthetic double-stranded RNA (dsRNA) that acts as a potent Toll-like receptor 3 (TLR3) agonist and immune adjuvant. By leveraging Hiltonol's ability to activate the innate immune system and enhance antigen presentation, the combination aims to elicit a robust, antigen-specific CD8+ T-cell response against tumor cells. The combination has been evaluated in Phase 1/2 clinical trials for recurrent glioblastoma multiforme.
- Other names
- Hiltonol + SL-701Poly ICLC + SL-701Poly ICLC + SL701Poly-ICLC + SL-701Poly-ICLC + SL701
02
Targets
IFIH1 (MDA5)BIRC5 (Survivin)TLR3 (Toll-like receptor 3)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)IL13RA2 (Interleukin-13 receptor subunit alpha 2)EPHA2 (Ephrin type-A receptor 2)
Beyond the preview
Go deeper on Hiltonol + SL701.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hiltonol + SL701.